FDA Approves New Blood Thinner to Cut Repeat Strokes
FDA Approves New Blood Thinner to Cut Repeat Strokes
FDA Approves New Blood Thinner to Cut Repeat Strokes
Key points
اہم نکات
मुख्य बातें
- A new blood thinner cut the risk of a repeat stroke by 26%, and the FDA approved it on Monday for adults who recently had a stroke or a mini-stroke.
- The once-daily pill, Sunharbo from Bayer, is the first drug of its kind — it blocks the clotting protein Factor XIa.
- In a 12,327-patient trial, 6.2% of patients on the drug had another stroke versus 8.4% on a placebo, with no significant rise in major bleeding.
- A new blood thinner cut the risk of a repeat stroke by 26%, and the FDA approved it on Monday for adults who recently had a stroke or a mini-stroke.
- The once-daily pill, Sunharbo from Bayer, is the first drug of its kind — it blocks the clotting protein Factor XIa.
- In a 12,327-patient trial, 6.2% of patients on the drug had another stroke versus 8.4% on a placebo, with no significant rise in major bleeding.
- A new blood thinner cut the risk of a repeat stroke by 26%, and the FDA approved it on Monday for adults who recently had a stroke or a mini-stroke.
- The once-daily pill, Sunharbo from Bayer, is the first drug of its kind — it blocks the clotting protein Factor XIa.
- In a 12,327-patient trial, 6.2% of patients on the drug had another stroke versus 8.4% on a placebo, with no significant rise in major bleeding.
A new blood thinner cut the risk of a repeat stroke by 26%, and the FDA approved it on Monday for adults who recently had a stroke or a mini-stroke. The once-daily pill, Sunharbo from Bayer, is the first drug of its kind — it blocks the clotting protein Factor XIa. In a 12,327-patient trial, 6.2% of patients on the drug had another stroke versus 8.4% on a placebo, with no significant rise in major bleeding. It costs $748.50 for a 30-day supply and is expected to ship this month.
A new blood thinner cut the risk of a repeat stroke by 26%, and the FDA approved it on Monday for adults who recently had a stroke or a mini-stroke. The once-daily pill, Sunharbo from Bayer, is the first drug of its kind — it blocks the clotting protein Factor XIa. In a 12,327-patient trial, 6.2% of patients on the drug had another stroke versus 8.4% on a placebo, with no significant rise in major bleeding. It costs $748.50 for a 30-day supply and is expected to ship this month.
A new blood thinner cut the risk of a repeat stroke by 26%, and the FDA approved it on Monday for adults who recently had a stroke or a mini-stroke. The once-daily pill, Sunharbo from Bayer, is the first drug of its kind — it blocks the clotting protein Factor XIa. In a 12,327-patient trial, 6.2% of patients on the drug had another stroke versus 8.4% on a placebo, with no significant rise in major bleeding. It costs $748.50 for a 30-day supply and is expected to ship this month.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।